Antimikrobnaya terapiya ventilyator-assotsiirovannoy pnevmonii: problemy rosta i rasprostraneniya rezistentnykh vozbuditeley
- Authors: Zuzova A.P1,2, Kozlov S.N1,2
-
Affiliations:
- Смоленская медицинская государственная академия
- НИИ антимикробной химиотерапии
- Issue: Vol 8, No 3 (2006)
- Pages: 30-36
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/92084
- ID: 92084
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A. P Zuzova
Смоленская медицинская государственная академия; НИИ антимикробной химиотерапииКафедра клинической фармакологии
S. N Kozlov
Смоленская медицинская государственная академия; НИИ антимикробной химиотерапииКафедра клинической фармакологии
References
- Bodmann K.F, Lorenz J, Bauer T.T et al. Nosocomial Pneumonia: Prevention, Diagnosis, and Treatment. Chemother J 2003; 12 (2): 33–44.
- Kollef M.H. Prevention of hospital – associated pneumonia and ventilator - associated pneumonia. Crit Care Med 2004; 32 (6): 1396–405.
- Empey K.M, Rapp R.P, Evans M.E. The effect of Antimicrobial formulary change on hospital resistance patterns. Pharmacother 2002; 22: 81–7.
- Mariscal D, Gallego M, Valles J, Rello J. Diagnosis of ventilator - associated pneumonia. Rev in Med Microbiol 2001; 12 (3): 143–53.
- Hyle E.P, Lipworth A.D, Zaoutis T.E et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended - spectrum b - lactamase - producing Enterobacteriaceae. Arch Intern Med 2005; 165: 1375-80.
- Гельфанд Б.Р., Гологорский В.А., Белоцерковский Б.З. и др. Consilium Medicum 2001; Приложение: 15–18.
- Руднов В.А. Вентилятор - ассоциированная пневмония: дискуссионные вопросы, терминологии, диагностики и эмпирической антибиотикотерапии Клин. микробиол. и антимикроб. химиотер. 2001; 3 (3): 198–207.
- Kwan Kew Lai et al. Impact of a Program of Intensive Survesiveillance and Interventions Targeting Ventilated Patients in the Reduction of Ventilator-Associated Pneumonia and its Cost-Effectiveness. Infect Control Hospital Epidemiol 2003; 24 (11): 859–63.
- Sintchenko V, Iredell J.R, Gilbert G.L Antibiotic therapy of ventilator - associated pneumonia – reappraisal of rationale in the era of bacterial resistance. Inter: J Fnt Agents 2001; 18: 223–9.
- Kollet M.H, Ward S, Sherman G et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28: 3456–64.
- Courvalin P. Evolutionary Courvalin P. Evolutionary strategy of antibiotic resistance. Bull Mem Acad R Med Belg 2002; 157: 301-8; discussion 308–9.
- Сидоренко С.В.,Страчункий Л.С., Ахмедова Л.И. и др. Результаты многоцентрового исследованиясравнительной активности цефепима и других антибиотиков в отношении возбудителей тяжелых госпитальных инфекций (программа "Микромакс" Антибиотики и химиотер. 1999; 44 (11): 7–16.
- Fourrier F, Cau-Potter E, Boutigly H et al. Effects of dental plaque antiseptic contamination on bacterial colonization and nosocomial infection in critical ill patients. Intensive Care Med 2000; 26: 1239–47.
- Agvald-Ohman C, Wernerman J, Nord C.E, Edlund C. Anaerobic bacteria commonly colonize the lower airways of intubated ICU patients. CMI, Original article 2003; 9: 397–405.
- Balthzar A.B, Von Nowakonski A, De Capitani E.V et al. Diagnostic investigation of ventilator – associated pneumonia using bronchoalveolar lavage: comparative study with a postmortem lung biopsy. BJM Biol Res 2001; 34 (8): 993–1001.
- Miller P.R, Meredith J.W, Chang M.C. Optimal threshold for diagnosis of ventilator - associated pneumonia using bronhoalveolar lavage. J Trauma 2003; 55: 263–7.
- Zanetti G, Bally F, Greub G et al. Cefepime versus imipinem - cilastatin for treatmen of nosocomial pneumonia in ICU patients’ a multicenter, evaluator - blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442–7.
- Rapid Antimicrobial Susceptibility Testing in patients with VAP: Direct E-Test on Respiratory Samples.
- Osmon S, Ward S, Fraser V.J, Kollef M.H. Hospital mortality for patients with bacteriemia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125 (2): 607–16.
- Zaoutis T.E, Goyal M, Chu J.H et al. Risk factors for and outcomes of bloodstream infection caused by extended - spectrum b - lactamase - producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115: 942–9.
- Grover S.S, Sharma M, Chattopadhya D, Kapoor H. Pasha Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: Emergence of high resistance against cefepime, the generation cephalosporin. J Infect 2006; 16: 101–22.
- Martin S.I, Kaye K.M. b - Lactam antibiotics: newer formulation and newer agents. Infect Dis Clin North Am 2004; 18: 603–19.
- Kessler R.E. Cefepime Microbiologic profile and update. Pediatr Infect Dis J 2001; 20: 331–66.
- Andes D.R, Craig W.A. Cephalosporins. In: Mandell G.L, Bennett J.E, Dolin R. (eds.) Principles Practice of Infection Diseases. Churchill Livingstone, 6th edition. 2004; 294–311.
- Эйдельштейн М.В. b-Лактамазы аэробных грамотрицательных бактерий: характеристика, основные принципы классификации, современные методы выявления и типирования. Клин. микробиол. антимикр. химиотер. 2001; 223–42.
- Grossman R.F, Campbell D.A, Landis S.J et al. Treatment of community - acquired pneumonia in the eldery: the role of cefepime, A fourth – generation cephalosporin. J Antimicrob Chemother 1999; 43: 549–54.
- Страчунский Л.С., Решедько Г.К., Эйдельштейн М.В. и др. Сравнительная активность цефепима и других антибиотиков в отношении нозокомиальных грамотрицательных возбудителей инфекций в России. Клин. микроб. антимикроб. химиотер. 2003; 5: 259–74.
- Wiener J, Quinn J.Р, Bradford P.A et al. Multiple antibiotic resistant Klebsiella spp. and Escherichia coli in nursing homes. JAMA 1999; 281: 517–23.
- Liang Yu W, Pfaller M.A, Winokur P.L, Jones R.N. Cefepime MIC as a predictor of the extended - spectrum 6-lactamase type in Klebsiella pneumoniae Taiwan. Emerging Infect Dis 2002; 8: 522–4.
- Emety C.L, Weymoulb L.A. Detection and clinical significance of extended spectrum b - lactamases in a tertiary care medical center. J Clin Microbiol 1997; 35: 2061– 7.
- Березин А.Г., Ромашов О.М., Яковлев С.Б, Сидоренко С.В. Антибиотики и химиотер. 2003; 48 (7): 5–11.
- Zanetti G et al. Ctfepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: Multicenter, Evaluator-Blind, Prospective, Randomized Study. Antim. Agents Chemother Nov. 2003; 3442–47.
- Lukasz Naumiuk Cefepim in vitro activity against derepressed extended - spectrum d - lactamase (ESBL) – produsing fnd not – ESBL – produsing Enterobacter cloacae by disc - diffusion method. J Antimicrob Chemother 2001; 48: 321–2.
- Burgess D.S, Hall R.G, Lewis J.S et al. Clinical and microbiologic analysis of a hospital's extended - spectrum b - lactamase - producing isolates over a 2-year period. Pharmacotherapy 2003; 23: 1232–7.
- Goethaert K, Van Looveren M, Lammens C et al. High - dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely - ill patients. Clin Microbiol Infect 2006; 12: 56–62.
- Grenwood D. b - lactam antibiotics cephalosporins In: R.G. Finch R.G. et al. Antibiotic Chemother 2003; 185–223.
- Kessier R.E. Cefepime microbiologic profile and update. Pediatr Infect Dis J 2001; 20: 331–66.
- Козлов Р.С. Нозокомиальные инфекции. Практическое руководство по антиинфекционной химиотерапии. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. 2002; с. 272–5.
- Jones R.N, Sader H.S, Beach M.N. Contemporary in vitro spectrum on activity summary for antimicrobial agents tested against 18569 strains non - fermentative Gram - negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001).
- Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, Apr. 2005; p. 87.
- Jones R.N, Sader H.S, Hoban D.J et аl. In vitro activity of selected Cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating т the SENTRY Antimicrobial Surveillance Program, 1997–1998. Diagn Microbiol Infect Dis 2000; 37: 93–8.
- Сидоренко С.В., Страчунский Л.С., Ахмедова Л.М. и др. Результаты многоцентрового исследованиясравнительной активности цефепима и других антибиотиков в отношении возбудителей тяжелых госпитальных инфекций. Антибиотики и химиотер. 1999; 11: 7.
- Hoban D.J, Biedenbach D.J, Mutnick A.H, Jones R.N. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized[patients in North America: results of the SENTR) Aintimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003; 45: 179–85.
- Козлов Р.С., Кречикова О.Л., Сивая O.В. и др. Антибиотикорезистентность Streptococcus рneumoniae в России, результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-1). Клин.микробиол. антимикроб, химиотер. 2002; 4: 267–77.
- Diffusion into Lung Tissue of Cefepime Administrated in Continuous Infusion in Patient with Nosocomial Pneumonia. E.Boselli, B.Allaouchiche, D.Breilh and al. Hotel – Dieu Hospital, Lion, France. 42nd ICAAC Abstract. 2002.
- Chastre J, Wolff M, Fagon J.Y et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator - associated pneumonia in adults. JAMA 2003; 290: 2588–98.
- Evaluation of the Activity o Carbapenem and Cephem Antibiotics against Pseudomonas aeruginosa Isolated from Hospitalized Patients. 1998. Kenji Nishizawa.
- Bernard E, Breilb D Bru J.P et al. Is there a rationales for the соntinious infusion of cefepime A multidisciplinary approach. Clin Mtcrobiol Infect 2003; 9: 339–48.
- Страчунский Л.С., Мягков А.С. Постоянная инфузия b - лактамов как альтернатива традиционным методам введения. Микробиол. антимикроб. химиотер. 2004; б: 32–50.
- Frei C.R, Burgess D.S. Continuous infusion b - lactams for intensive care unit pulmonary infections. Clin Microb Infect 2005; 11: 418–21.
- Stability and Antibacterial Activity of Cefepime during continious Infusion Antimicrob Agents Chemother 2003; 47 (6): 1991–5.
- Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV – infected patient: an open, randomized trial. J Antimicrob Chemother 2001; 48: 527–34.
- Beaucaire G, Nicolas M.H, Mortan С et al. Comparative study of combined cefepime - arnikacin versus ceftazidime combined with amikadn m the treatment nosocomial pneumonias in ventilated patients. Multicenter group study. Ann Fr Anesth Reanim 1999; 18: 186–95.
- Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Нозокомиальная пневмония у взрослых: фактические рекомендации по диагностике, лечению и профилактике, пособие для врачей. 2005.
Supplementary files
